Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
accepted:
26
08
2019
pubmed:
9
10
2019
medline:
22
4
2020
entrez:
10
10
2019
Statut:
ppublish
Résumé
Local administration of oncolytic viruses to tumours can promote anticancer immune responses that lead to the abscopal regression of distant metastases, especially in patients receiving systemic immune-checkpoint inhibitors. Growing preclinical evidence indicates that non-virally induced oncolysis, defined as chemical or physical treatment administered locally to destroy malignant lesions, can promote a similar effect owing to the release of danger-associated molecular patterns that lead to the recruitment of immune cells, thus inducing a systemic response against tumour antigens that protects against local disease relapse and also mediates distant antineoplastic effects. An accumulating body of preclinical evidence supports the implementation of therapies that combine oncolysis with local or systemic immunotherapies. In this Review, we summarize the available data on innovative non-viral oncolysis strategies, including intratumorally applied cytotoxicants, photodynamic therapy, laser therapy, microwave, radiofrequency or photothermal ablation, high-intensity focused ultrasonography and cryotherapy for the local treatment of patients with solid tumours.
Identifiants
pubmed: 31595049
doi: 10.1038/s41571-019-0272-7
pii: 10.1038/s41571-019-0272-7
doi:
Substances chimiques
Antineoplastic Agents
0
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-64Références
Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690–714 (2015).
pubmed: 26678337
doi: 10.1016/j.ccell.2015.10.012
Dadi, S. et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365–377 (2016).
pubmed: 26806130
pmcid: 4733424
doi: 10.1016/j.cell.2016.01.002
Fridman, W. H., Zitvogel, L., Sautes-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).
pubmed: 28741618
doi: 10.1038/nrclinonc.2017.101
Fucikova, J. et al. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res. 76, 1746–1756 (2016).
pubmed: 26842877
doi: 10.1158/0008-5472.CAN-15-1142
Pages, F. et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018).
pubmed: 29754777
doi: 10.1016/S0140-6736(18)30789-X
Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y. X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365–379 (2017).
pubmed: 28094262
doi: 10.1038/nrclinonc.2016.211
Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931 (2012).
pubmed: 22397654
pmcid: 3345206
doi: 10.1056/NEJMoa1112824
De Meerleer, G. et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 15, e170–e177 (2014).
pubmed: 24694640
doi: 10.1016/S1470-2045(13)70569-2
Mothersill, C., Rusin, A., Fernandez-Palomo, C. & Seymour, C. History of bystander effects research 1905-present; what is in a name? Int. J. Radiat. Biol. 94, 696–707 (2018).
pubmed: 29095061
doi: 10.1080/09553002.2017.1398436
Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313–322 (2018).
pubmed: 29449659
pmcid: 5912991
doi: 10.1038/nrc.2018.6
Rodriguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C. & Demaria, S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39, 644–655 (2018).
pubmed: 30001871
pmcid: 6326574
doi: 10.1016/j.it.2018.06.001
Lin, A. J., Roach, M., Bradley, J. & Robinson, C. Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. Transl Lung Cancer Res. 8, 107–115 (2019).
pubmed: 30788240
pmcid: 6351396
doi: 10.21037/tlcr.2018.08.16
Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).
pubmed: 28598415
pmcid: 5472757
doi: 10.1038/ncomms15618
Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845–1851 (2018).
pubmed: 30397353
pmcid: 6286242
doi: 10.1038/s41591-018-0232-2
Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662 (2015).
pubmed: 26323545
pmcid: 7097180
doi: 10.1038/nrd4663
Achard, C. et al. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine 31, 17–24 (2018).
pubmed: 29724655
pmcid: 6013846
doi: 10.1016/j.ebiom.2018.04.020
Greig, S. L. Talimogene laherparepvec: first global approval. Drugs 76, 147–154 (2016).
pubmed: 26620366
doi: 10.1007/s40265-015-0522-7
Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119.e10 (2017).
pubmed: 28886381
pmcid: 8034392
doi: 10.1016/j.cell.2017.08.027
Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36, 1658–1667 (2018).
pubmed: 28981385
doi: 10.1200/JCO.2017.73.7379
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C. & Nelson, B. H. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat. Rev. Cancer 18, 419–432 (2018).
pubmed: 29695749
doi: 10.1038/s41568-018-0009-4
Bommareddy, P. K., Shettigar, M. & Kaufman, H. L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498–513 (2018).
pubmed: 29743717
doi: 10.1038/s41577-018-0014-6
G Pol, J. et al. Trial watch: oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology 7, e1503032 (2018).
doi: 10.1080/2162402X.2018.1503032
Harrington, K. J. et al. A practical guide to the handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther. 10, 3867–3880 (2017).
pubmed: 28814886
pmcid: 5546812
doi: 10.2147/OTT.S133699
Martin, C. Oncolytic viruses: treatment and implications for patients with gliomas. Clin. J. Oncol. Nurs. 21, 60–64 (2017).
pubmed: 28315557
doi: 10.1188/17.CJON.S2.60-64
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P. & Spisek, R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 3, e968434 (2015).
pubmed: 25964865
pmcid: 4352954
doi: 10.4161/21624011.2014.968434
Chu, K. F. & Dupuy, D. E. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer 14, 199–208 (2014).
pubmed: 24561446
doi: 10.1038/nrc3672
Slovak, R., Ludwig, J. M., Gettinger, S. N., Herbst, R. S. & Kim, H. S. Immuno-thermal ablations - boosting the anticancer immune response. J. Immunother. Cancer 5, 78 (2017).
pubmed: 29037259
pmcid: 5644150
doi: 10.1186/s40425-017-0284-8
Schneider, T. et al. Immune response after radiofrequency ablation and surgical resection in nonsmall cell lung cancer. Semin. Thorac. Cardiovasc. Surg. 28, 585–592 (2016).
pubmed: 28043482
doi: 10.1053/j.semtcvs.2016.02.008
Chen, Q. et al. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells. Adv. Mater. 31, e1900192 (2019).
pubmed: 30916367
pmcid: 7262962
doi: 10.1002/adma.201900192
den Brok, M. H. et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br. J. Cancer 95, 896–905 (2006).
doi: 10.1038/sj.bjc.6603341
Jansen, M. C. et al. Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 147, 686–695 (2010).
pubmed: 20042207
doi: 10.1016/j.surg.2009.10.053
Sabel, M. S. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 58, 1–11 (2009).
pubmed: 19007768
doi: 10.1016/j.cryobiol.2008.10.126
Kato, T. et al. Characterization of the cryoablation-induced immune response in kidney cancer patients. Oncoimmunology 6, e1326441 (2017).
pubmed: 28811963
pmcid: 5543848
doi: 10.1080/2162402X.2017.1326441
Zhao, J. et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat. Commun. 10, 899 (2019).
pubmed: 30796212
pmcid: 6385305
doi: 10.1038/s41467-019-08782-1
Pandit, H. et al. Evaluating the regulatory immunomodulation effect of irreversible electroporation (IRE) in pancreatic adenocarcinoma. Ann. Surg. Oncol. 26, 800–806 (2019).
pubmed: 30610562
doi: 10.1245/s10434-018-07144-3
White, S. B., Zhang, Z., Chen, J., Gogineni, V. R. & Larson, A. C. Early immunologic response of irreversible electroporation versus cryoablation in a rodent model of pancreatic cancer. J. Vasc. Interv. Radiol. 29, 1764–1769 (2018).
pubmed: 30316676
doi: 10.1016/j.jvir.2018.07.009
Calvet, C. Y., Famin, D., Andre, F. M. & Mir, L. M. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 3, e28131 (2014).
pubmed: 25083316
pmcid: 4111940
doi: 10.4161/onci.28131
Bugaut, H. et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLOS ONE 8, e65181 (2013).
pubmed: 23762310
pmcid: 3676388
doi: 10.1371/journal.pone.0065181
Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691–1701 (2005).
pubmed: 16365148
pmcid: 2212968
doi: 10.1084/jem.20050915
Tremble, L. F., O’Brien, M. A., Soden, D. M. & Forde, P. F. Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer. Cancer Lett. 442, 475–482 (2019).
pubmed: 30472183
doi: 10.1016/j.canlet.2018.11.015
Garg, A. D. et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 31, 1062–1079 (2012).
pubmed: 22252128
pmcid: 3298003
doi: 10.1038/emboj.2011.497
Gomes-da-Silva, L. C. et al. Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. EMBO J. 37, e98354 (2018).
pubmed: 29807932
pmcid: 6028029
doi: 10.15252/embj.201798354
Preise, D. et al. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol. Immunother. 58, 71–84 (2009).
pubmed: 18488222
doi: 10.1007/s00262-008-0527-0
Kleinovink, J. W., Fransen, M. F., Lowik, C. W. & Ossendorp, F. Photodynamic-immune checkpoint therapy eradicates local and distant tumors by CD8
pubmed: 28851692
doi: 10.1158/2326-6066.CIR-17-0055
Cho, A., Jantschitsch, C. & Knobler, R. Extracorporeal photopheresis-an overview. Front. Med. 5, 236 (2018).
doi: 10.3389/fmed.2018.00236
Edelson, R. et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N. Engl. J. Med. 316, 297–303 (1987).
pubmed: 3543674
doi: 10.1056/NEJM198702053160603
Ventura, A. et al. Extracorporeal photochemotherapy drives monocyte-to-dendritic cell maturation to induce anticancer immunity. Cancer Res. 78, 4045–4058 (2018).
pubmed: 29764863
doi: 10.1158/0008-5472.CAN-18-0171
Habib, A. et al. Transarterial approaches to primary and secondary hepatic malignancies. Nat. Rev. Clin. Oncol. 12, 481–489 (2015).
pubmed: 25985939
doi: 10.1038/nrclinonc.2015.78
Lee, H. L. et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci. Rep. 9, 3260 (2019).
pubmed: 30824840
pmcid: 6397294
doi: 10.1038/s41598-019-40078-8
Obeid, M. et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14, 1848–1850 (2007).
pubmed: 17657249
doi: 10.1038/sj.cdd.4402201
Chew, V. et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 68, 335–346 (2019).
pubmed: 29440463
doi: 10.1136/gutjnl-2017-315485
Pasquereau-Kotula, E., Habault, J., Kroemer, G. & Poyet, J. L. The anticancer peptide RT53 induces immunogenic cell death. PLOS ONE 13, e0201220 (2018).
pubmed: 30080874
pmcid: 6078289
doi: 10.1371/journal.pone.0201220
Zhou, H. et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 7, e2134 (2016).
pubmed: 26962684
pmcid: 4823948
doi: 10.1038/cddis.2016.47
Zhou, H. et al. The oncolytic compound LTX-401 targets the Golgi apparatus. Cell Death Differ. 23, 2031–2041 (2016).
pubmed: 27588704
pmcid: 5136493
doi: 10.1038/cdd.2016.86
Zhou, H. et al. Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. Cell Death Dis. 9, 1086 (2018).
pubmed: 30352991
pmcid: 6199251
doi: 10.1038/s41419-018-1127-3
Nestvold, J. et al. Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. Oncoimmunology 6, e1338236 (2017).
pubmed: 28920000
pmcid: 5593701
doi: 10.1080/2162402X.2017.1338236
Camilio, K. A. et al. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. Breast Cancer Res. 21, 9 (2019).
pubmed: 30670061
pmcid: 6343247
doi: 10.1186/s13058-018-1092-x
Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715–727 (2006).
pubmed: 16977338
doi: 10.1038/nri1936
Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
pubmed: 21436444
doi: 10.1126/science.1203486
Palucka, A. K. & Coussens, L. M. The basis of oncoimmunology. Cell 164, 1233–1247 (2016).
pubmed: 26967289
pmcid: 4788788
doi: 10.1016/j.cell.2016.01.049
Chaurasiya, S., Chen, N. G. & Fong, Y. Oncolytic viruses and immunity. Curr. Opin. Immunol. 51, 83–90 (2018).
pubmed: 29550660
doi: 10.1016/j.coi.2018.03.008
Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659 (1986).
pubmed: 3537791
doi: 10.1056/NEJM198612253152606
Bloy, N. et al. Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol. Rev. 280, 165–174 (2017).
pubmed: 29027230
doi: 10.1111/imr.12582
Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2007).
pubmed: 17187072
doi: 10.1038/nm1523
Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573–1577 (2011).
pubmed: 22174255
doi: 10.1126/science.1208347
Martins, I. et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 21, 79–91 (2014).
pubmed: 23852373
doi: 10.1038/cdd.2013.75
Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353–363 (2009).
pubmed: 19365408
pmcid: 2818721
doi: 10.1038/nri2545
Blander, J. M. & Medzhitov, R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808–812 (2006).
pubmed: 16489357
doi: 10.1038/nature04596
Ali, M. Y. et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J. Hepatol. 43, 817–822 (2005).
pubmed: 16087270
doi: 10.1016/j.jhep.2005.04.016
Fietta, A. M. et al. Systemic inflammatory response and downmodulation of peripheral CD25
pubmed: 19332094
doi: 10.1016/j.humimm.2009.03.012
Chen, T., Guo, J., Han, C., Yang, M. & Cao, X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J. Immunol. 182, 1449–1459 (2009).
pubmed: 19155492
doi: 10.4049/jimmunol.182.3.1449
Sabel, M. S. et al. Immunologic response to cryoablation of breast cancer. Breast Cancer Res. Treat 90, 97–104 (2005).
pubmed: 15770533
doi: 10.1007/s10549-004-3289-1
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).
pubmed: 26027717
doi: 10.1038/nri3845
Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).
pubmed: 27748397
doi: 10.1038/nri.2016.107
Masopust, D. & Soerens, A. G. Tissue-resident T cells and other resident leukocytes. Annu. Rev. Immunol. 37, 521–546 (2019).
pubmed: 30726153
pmcid: 7175802
doi: 10.1146/annurev-immunol-042617-053214
Tang, J. et al. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat. Rev. Drug Discov. 17, 854–855 (2018).
pubmed: 30482962
doi: 10.1038/nrd.2018.210
Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).
pubmed: 30345906
doi: 10.1056/NEJMoa1809615
Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).
pubmed: 29863955
doi: 10.1056/NEJMoa1716948
Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343–354 (2016).
pubmed: 26872698
pmcid: 4758865
doi: 10.1016/j.immuni.2015.11.024
Liu, P. et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat. Commun. 10, 1486 (2019).
pubmed: 30940805
pmcid: 6445096
doi: 10.1038/s41467-019-09415-3
Rios-Doria, J. et al. Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 77, 2686–2698 (2017).
pubmed: 28283653
doi: 10.1158/0008-5472.CAN-16-2854
Yamazaki, T. et al. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 23, 1004–1015 (2016).
pubmed: 27082453
pmcid: 4987735
doi: 10.1038/cdd.2016.35
Zhu, J. et al. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: a pre-clinical study in a murine model. Diagn. Interv. Imaging 99, 135–142 (2018).
pubmed: 29398572
doi: 10.1016/j.diii.2017.12.011
Shi, L. et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin. Cancer Res. 22, 1173–1184 (2016).
pubmed: 26933175
pmcid: 4780056
doi: 10.1158/1078-0432.CCR-15-1352
O’Shaughnessy, M. J. et al. Systemic antitumor immunity by PD-1/PD-L1 inhibition is potentiated by vascular-targeted photodynamic therapy of primary tumors. Clin. Cancer Res. 24, 592–599 (2018).
pubmed: 28954788
doi: 10.1158/1078-0432.CCR-17-0186
Adashek, J. J., Salgia, M., Dizman, N., Kessler, J. & Pal, S. K. Concomitant radioembolization and immune checkpoint inhibition in metastatic renal cell carcinoma. Case Rep. Oncol. 11, 276–280 (2018).
pubmed: 29867435
pmcid: 5981597
doi: 10.1159/000489995
Wehrenberg-Klee, E., Goyal, L., Dugan, M., Zhu, A. X. & Ganguli, S. Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 41, 1799–1802 (2018).
pubmed: 29845347
doi: 10.1007/s00270-018-1993-1
Zheng, J., Irani, Z., Lawrence, D., Flaherty, K. & Arellano, R. S. Combined effects of yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series. J. Vasc. Interv. Radiol. 29, 1369–1375 (2018).
pubmed: 30174161
doi: 10.1016/j.jvir.2018.04.030
Waitz, R. et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72, 430–439 (2012).
pubmed: 22108823
doi: 10.1158/0008-5472.CAN-11-1782
Mozzillo, N. et al. Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncoimmunology 4, e1008842 (2015).
pubmed: 26155423
pmcid: 4485758
doi: 10.1080/2162402X.2015.1008842
Theurich, S. et al. Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol. Res. 4, 744–754 (2016).
pubmed: 27466265
doi: 10.1158/2326-6066.CIR-15-0156
Xie, C. et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology 69, 2048–2060 (2019).
pubmed: 30578687
doi: 10.1002/hep.30482
Behm, B. et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut 65, 134–143 (2016).
pubmed: 25524262
doi: 10.1136/gutjnl-2014-308286
Lin, M. et al. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. Oncotarget 8, 101795–101807 (2017).
pubmed: 29254205
pmcid: 5731915
doi: 10.18632/oncotarget.21974
Yang, Y. et al. Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer. Cardiovasc. Intervent. Radiol. 42, 48–59 (2019).
pubmed: 30151798
doi: 10.1007/s00270-018-2069-y
Bear, A. S. et al. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLOS ONE 8, e69073 (2013).
pubmed: 23935927
pmcid: 3720863
doi: 10.1371/journal.pone.0069073
Marabelle, A. et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123, 2447–2463 (2013).
pubmed: 23728179
pmcid: 3668834
doi: 10.1172/JCI64859
Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral immunotherapy: using the tumor as the remedy. Ann. Oncol. 28, xii33–xii43 (2017).
pubmed: 29253115
doi: 10.1093/annonc/mdx683
Frank, M. J. et al. In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma. Cancer Discov. 8, 1258–1269 (2018).
pubmed: 30154192
pmcid: 6171524
doi: 10.1158/2159-8290.CD-18-0743
Sagiv-Barfi, I. et al. Eradication of spontaneous malignancy by local immunotherapy. Sci. Transl Med. 10, eaan4488 (2018).
pubmed: 29386357
pmcid: 5997264
doi: 10.1126/scitranslmed.aan4488
Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814–824 (2019).
pubmed: 30962585
doi: 10.1038/s41591-019-0410-x
Li, L. et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J. Transl Med. 15, 23 (2017).
pubmed: 28137271
pmcid: 5282633
doi: 10.1186/s12967-017-1124-9
Lemdani, K. et al. Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma. Oncoimmunology 8, 1550342 (2019).
pubmed: 30723580
pmcid: 6350685
doi: 10.1080/2162402X.2018.1550342
Veenstra, J. J. et al. Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. Cancer Res. 74, 5409–5420 (2014).
pubmed: 25092895
pmcid: 4185007
doi: 10.1158/0008-5472.CAN-14-0501
Machlenkin, A. et al. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin. Cancer Res. 11, 4955–4961 (2005).
pubmed: 16000595
doi: 10.1158/1078-0432.CCR-04-2422
Alteber, Z. et al. Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. Cancer Immunol. Immunother. 63, 369–380 (2014).
pubmed: 24452202
doi: 10.1007/s00262-014-1520-4
Chua, C. Y. X. et al. Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. J. Control. Release 285, 23–34 (2018).
pubmed: 30008369
doi: 10.1016/j.jconrel.2018.06.035
Luo, L. et al. Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors. J. Control. Release 278, 87–99 (2018).
pubmed: 29626502
doi: 10.1016/j.jconrel.2018.04.002
Chen, Q. et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat. Commun. 7, 13193 (2016).
pubmed: 27767031
pmcid: 5078754
doi: 10.1038/ncomms13193
Andtbacka, R. H. et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the optim phase III clinical trial. Ann. Surg. Oncol. 23, 4169–4177 (2016).
pubmed: 27342831
pmcid: 5090012
doi: 10.1245/s10434-016-5286-0
Chao, Y. et al. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses. Nat. Biomed. Eng. 2, 611–621 (2018).
pubmed: 31015634
doi: 10.1038/s41551-018-0262-6
Chen, Q. et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat. Nanotechnol. 14, 89–97 (2019).
pubmed: 30531990
doi: 10.1038/s41565-018-0319-4
Abdo, J., Cornell, D. L., Mittal, S. K. & Agrawal, D. K. Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers. Front. Oncol. 8, 85 (2018).
pubmed: 29644213
pmcid: 5882833
doi: 10.3389/fonc.2018.00085
Fu, J. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl Med. 7, 283ra52 (2015).
pubmed: 25877890
pmcid: 4504692
Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl Med. 6, 226ra32 (2014).
pubmed: 24598590
pmcid: 4106918
doi: 10.1126/scitranslmed.3008095
Postel-Vinay, S. et al. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann. Oncol. 27, 214–224 (2016).
pubmed: 26578728
doi: 10.1093/annonc/mdv550
Skolnik, J. M., Barrett, J. S., Jayaraman, B., Patel, D. & Adamson, P. C. Shortening the timeline of pediatric phase I trials: the rolling six design. J. Clin. Oncol. 26, 190–195 (2008).
pubmed: 18182661
doi: 10.1200/JCO.2007.12.7712
Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 20, 404–416 (2019).
pubmed: 30918367
doi: 10.1038/s41576-019-0114-6
Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751–765.e16 (2018).
pubmed: 30318143
doi: 10.1016/j.cell.2018.09.018
Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
pubmed: 30894752
pmcid: 6954100
doi: 10.1038/s41586-019-1032-7
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & Lopez-Soto, A. The hallmarks of successful anticancer immunotherapy. Sci. Transl Med. 10, eaat7807 (2018).
pubmed: 30232229
doi: 10.1126/scitranslmed.aat7807
Engelhard, V. H. et al. Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity. J. Immunol. 200, 432–442 (2018).
pubmed: 29311385
doi: 10.4049/jimmunol.1701269
Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312–1326 (2014).
pubmed: 25480296
pmcid: 4437213
doi: 10.1016/j.cell.2014.11.018
Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765.e17 (2017).
pubmed: 28475900
pmcid: 5737939
doi: 10.1016/j.cell.2017.04.014
Lewis, K. L. et al. Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine. Immunity 35, 780–791 (2011).
pubmed: 22018469
pmcid: 3225703
doi: 10.1016/j.immuni.2011.08.013
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T. F. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359, 1366–1370 (2018).
pubmed: 29567708
doi: 10.1126/science.aar6918
Fend, L. et al. Immune checkpoint blockade, immunogenic chemotherapy or IFN-α blockade boost the local and abscopal effects of oncolytic virotherapy. Cancer Res. 77, 4146–4157 (2017).
pubmed: 28536278
doi: 10.1158/0008-5472.CAN-16-2165
Seremet, T. et al. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. Melanoma Res. 29, 85–88 (2019).
pubmed: 30211812
doi: 10.1097/CMR.0000000000000501
Woodland, D. L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25, 98–104 (2004).
pubmed: 15102369
doi: 10.1016/j.it.2003.11.009
Vrankar, M. & Unk, M. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. Radiol. Oncol. 52, 365–369 (2018).
pubmed: 30367809
pmcid: 6287173
doi: 10.2478/raon-2018-0037
Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).
pubmed: 26014293
doi: 10.1200/JCO.2014.58.3377
Marabelle, A. et al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann. Oncol. 29, 2163–2174 (2018).
pubmed: 30295695
pmcid: 6290929
doi: 10.1093/annonc/mdy423
Gujar, S., Pol, J. G., Kim, Y., Lee, P. W. & Kroemer, G. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends Immunol. 39, 209–221 (2018).
pubmed: 29275092
doi: 10.1016/j.it.2017.11.006
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=&term=Cryosurgery%2C+Fuda+Cancer+Hospital%2C+Guangzhou.&cntry=CN&state=&city=&dist= (2019)